Oncology and Hematology

Episodes 145-160 of 397

Emerging targeted therapy combination strategies in genitourinary malignancies
Emerging targeted therapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging targeted therapy combination strategies in genitourinary malignancies
1.25 program credits
- Ignacio Duran, MD
1.25 program credits
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
MinuteCE®
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
1.00 program credit
- Nicoletta Colombo, MD
1.00 program credit
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
MinuteCE®
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
1.25 program credits
- Ignacio Duran, MD
- Sandy Srinivas, MD
1.25 program credits
Emerging immunotherapy combination strategies in genitourinary malignancies
Emerging immunotherapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging immunotherapy combination strategies in genitourinary malignancies
1.25 program credits
- Sandy Srinivas, MD
1.25 program credits
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
MinuteCE®
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
1.00 program credit
- Susana Campos, MD, MPH
- Ritu Salani, MD, MBA
1.00 program credit
Treating R/R Classic Hodgkin Lymphoma: Ipilimumab and Other Approaches
Treating R/R Classic Hodgkin Lymphoma: Ipilimumab and Other Approaches
Project Oncology®
Treating R/R Classic Hodgkin Lymphoma: Ipilimumab and Other Approaches
Supplements and Cannabis in Breast Cancer Care: An Integrative Medicine Approach
Supplements and Cannabis in Breast Cancer Care: An Integrative Medicine Approach
Project Oncology®
Supplements and Cannabis in Breast Cancer Care: An Integrative Medicine Approach
- Heather Greenlee, ND, PhD, MPH
The Potential Link Between COVID-19 and Cancer Regression
The Potential Link Between COVID-19 and Cancer Regression
Clinician's Roundtable
The Potential Link Between COVID-19 and Cancer Regression
- Ankit Bharat, MD
Understanding iMCD Through RNA Sequencing
Understanding iMCD Through RNA Sequencing
Project Oncology®
Understanding iMCD Through RNA Sequencing
- Michael Gonzalez, PhD, MSc
The Future of ITP Care: Exploring New Treatments
The Future of ITP Care: Exploring New Treatments
Project Oncology®
The Future of ITP Care: Exploring New Treatments
- Michele Lambert, MD, MSTR
NSCLC Care: Predicting Response to Dato-DXd with a TROP2 Biomarker
NSCLC Care: Predicting Response to Dato-DXd with a TROP2 Biomarker
Project Oncology®
NSCLC Care: Predicting Response to Dato-DXd with a TROP2 Biomarker
- Jacob Sands, MD
- Marina Garassino, MD
Revolutionizing Breast Cancer Care: The Emerging Role of Liquid Biopsy Technologies
Revolutionizing Breast Cancer Care: The Emerging Role of Liquid Biopsy Technologies
Project Oncology®
Revolutionizing Breast Cancer Care: The Emerging Role of Liquid Biopsy Technologies
- Heather A. Parsons, MD, MPH
Diagnosing Castleman Disease: Key Considerations
Diagnosing Castleman Disease: Key Considerations
Project Oncology®
Diagnosing Castleman Disease: Key Considerations
- Mateo Bustamante
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
Project Oncology®
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
- Joshua Brandstadter, MD, PhD, MSc
Insights from global key opinion leaders on optimizing patient care in NSCLC
Insights from global key opinion leaders on optimizing patient care in NSCLC
MinuteCE®
Insights from global key opinion leaders on optimizing patient care in NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
MinuteCE®
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit